Cologuard - EXAS Net earnings per share for the last four quarters

Official company branding of Exact Sciences Corp (EXAS)

Exact Sciences generates revenue through the implementation of high-tech molecular tests Cologuard and Oncotype DX. The growth rate of net income per share YoY ttm clearly demonstrates the profitability trend, where the latest figure stands at 79.50. However, it is necessary to critically assess the dependence on clinic partnerships and the current liquidity surplus, which forms the company's essential financial reserve.

EXAS Cologuard: Net earnings per share (EPS TTM) in the range 02/11/2024 - 04/04/2026

Cologuard - analytical breakdowns and key metrics (EXAS)

- market price and analyst price targets:
Market Chart exactsciences.com|EXAS - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Exact Sciences Corp|EXAS - Total Company Value
- book value of equity indicators:
Net Assets per Share Exact Sciences|EXAS - Book Capitalization|Market-to-Book Ratio exactsciences.com|EXAS - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Ratio Exact Sciences|EXAS - Long-Term Debt to Capital|Short-Term Debt to Capital Exact Sciences Inc.|EXAS - Company Aggregate Debts|Debt to Book Value Exact Sciences Corp|EXAS - Company Long-Term Liabilities|Amount of Current Liabilities Exact Sciences|Intermediate Coverage Ratio exactsciences.com
- business earnings and investment ratios data:
EXAS - Company Net Income|Company Profit Forecast Exact Sciences|EXAS - P/E Multiple|Projected Price to Earnings Exact Sciences Corp|EXAS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Exact Sciences Corp|EXAS - Operating profit EBITDA|Net earnings per one share for the last twelve months Exact Sciences|EXAS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months exactsciences.com|EXAS - Earnings growth in current year|Expected earnings per share growth for next year Exact Sciences
- sales and revenue indicators:
EXAS - Revenue and Sales Volume|Company Expected Sales Volume exactsciences.com|EXAS - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Exact Sciences Corp
Fundamental company valuation:Exact Sciences
Finished products of Cologuard

The implementation of the Exact Sciences strategy to introduce non-invasive cancer diagnostics is reflected in the year-over-year (TTM) EPS comparison. This metric measures the dynamics of net profit per share over a rolling year, excluding short-term market noise. The current value of 79.50 demonstrates the scaling efficiency of Cologuard and investments in multi-cancer tests. The steady growth of this indicator confirms the fundamental resilience of the business in the face of technological competition.

Direct competitors

Net earnings per share for the last four quarters agilent.com A|DGX: Net earnings per share (EPS TTM)|ILMN - Net earnings per share for the last four quarters|Earnings per share for the last twelve months PerkinElmer|Bio-Rad Corp (BIO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) NNNN|SHC - Net earnings per one share for the last twelve months|QuidelOrtho Corporation - Net earnings per share for the last 12 months|OPK: Earnings per share for the last 12 months|CareDx Health - Net earnings per share (EPS TTM)|MRVI - Net earnings per share (EPS TTM)|FLGT: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months fluidigm.com|Net earnings per share for the last 12 months CTKB|OSUR (OraSure Technologies, Inc.) - Earnings per share for the last four quarters|Net earnings per share for the last 12 months XGN (Exagen Inc.)|MDXH (MDxHealth, Inc.) - Earnings per share for the trailing year|Earnings per share for the last twelve months Lucid Diagnostics Inc. LUCD|Net earnings per share for the last four quarters Prenetics Global Limited (PRE)|Insight Molecular - Net earnings per share (EPS TTM)|Trinity Biotech plc (TRIB) - Net earnings per share for the last 12 months|PRPH: Net earnings per share (EPS TTM)|AIMD - Net earnings per share for the last four quarters|CODX (Co-Diagnostics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months heartsciences.com HSCS|Earnings per share for the last twelve months Biomerica (BMRA)|cardiodiagnosticsinc.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ONCO (Onconetix Corp)|VRAX - Net earnings per share for the last 12 months|Bluejay Diagnostics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months aspirawh.com|Accelerate Diagnostics, Inc. (AXDX) - Earnings per share for the last twelve months|CNTG - Net earnings per share for the last four quarters|ENZ (Enzo Biochem Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Fresh2 FRES|Net earnings per share for the last 12 months GENE (Genetic Technologies)|23andme.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) PMD (Psychemedics Corporation)